Executive Interviews
Silent Pain and Smart Monitors: The High-Stakes Race to De-Risk the Operating Theatre
Anesthesia has long been considered more “art” than science, leaving clinicians to manage high-stakes sedation with aging tools. Cortical Dynamics is changing the clinical reality with BARM 2.0—an AI-powered monitor that provides real-time visibility into the brain’s response to pain and sedation, backed by a global licence and cooperation agreement with Philips and a decade of R&D.
The $3 Billion Blind Spot: How Venstra Medical is using “Collapsible” Physics to Challenge a Global Med-Tech Giant
In the high-stakes theater of the cath lab, cardiogenic shock is the ultimate emergency. Now, a PhD in fluid mechanics and a frontline cardiologist are deploying a “collapsible” breakthrough to disrupt a 30-year monopoly. The Engineer’s Mission For Dr. Martin Cook, the stakes of medical engineering aren’t measured in blueprints, but in heartbeats. A PhD […]
The Blue-Collar ‘Muscle’ Behind Australia’s $100bn Pipeline: One Key Resources Eyes Expansion
As Australia faces a “perfect storm” of low unemployment and an ambitious $100bn project pipeline, One Key Resources MD Ben Lewis explains why the next five years will be defined by the “muscle power” required to deliver the nation’s energy and infrastructure goals.
Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis
Cartherics is bridging the gap in women’s health by utilising iPSC-derived Natural Killer cells to target both ovarian cancer and endometriosis. With a proprietary manufacturing facility and a lead candidate heading to Phase 1 trials, the company is industrialising cell therapy to solve a multi-billion dollar unmet need.
The Billion-Dollar Blind Spot: The Australian Tech Making ‘Invisible’ Decay a Visible Asset for Investors
Incisive Technologies is moving dentistry from “restorative” to “preventative.” By detecting decay at 30 microns—long before it appears on an X-ray—their FDA-approved BlueCheck tool is eliminating the industry’s “watch and wait” mantra and opening a massive new frontier for clinical and at-home oral health monitoring.
The New ‘Blue’ Gold: Canopy Blue’s $10bn Bet on the Humble Seaweed
What if the answer to soil degradation was underwater? Canopy Blue CEO Josh Masel discusses the “commercial moat” of seaweed aquaculture and the massive offtake potential in animal feed and pharmaceuticals.
From Lick Blocks to Ledger: Why This ‘Boring’ Tech is the New AgTech Gold
In the Australian Outback, 92% of livestock live in extensive grazing systems where consistent nutrition is a logistical nightmare. Mark Peart is changing that by turning the “last mile” of farming into a digital ledger. Learn how DIT AgTech’s uDOSE™ platform is bridging the gap between generational legacy and the global carbon market.
Blockchain, Biometrics, and Bullion: How Kavach is Digitising the Family Safe
As Australian banks phase out physical safety lockers, Kavach is stepping in with a high-tech network of suburban vaults. Combining AI threat detection with private blockchain verification, founder Dinesh Dindukurthi is digitising the family safe for a new generation of wealth.
Australia’s 60,000 Business Succession Crisis: Why Good Companies Will Close Their Doors
The Australian Business Growth Fund identified approximately 162,000 privately held businesses in Australia with revenue between AUD$2 million and AUD$100 million. More than two-thirds are owned by people of retirement age. When surveyed, another two-thirds do not have a succession plan in place. The mathematics are stark. 60,000 businesses owned by someone of retirement age […]
Backed By Leading Investment Groups and Family Offices
